Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:22:12.454Z.
Calculation as of: 2026-10-06T14:22:12.454Z.
Quote observation: 2026-10-06T14:20:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a3e1feeb410069f07e4350e21f058018b4d4b1a35d97054c3a706da9d6a2f8d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$84.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.89M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.55M
Price/OCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
Market Cap
$82.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.83M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $84.03M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.20M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $84.98M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.89M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $83.18M | N/A | 111.15 | 111.15 | 111.15 |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.55M | N/A | 17.74 | 16.00 | 17.53 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $82.35M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 3.25 | 4.27 | 2.78 | 3.26 |
| Citius Oncology, Inc. (CTOR)vs › | $81.83M | N/A | 786.57 | 786.57 | 786.57 |
| LENSAR Inc (LNSR)vs › | $81.98M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
